A Smartphone App on Medication Adherence

• Conditions: Medication Adherence
• Interventions: Behavioral: the MedAdhere app

• Registration Number: NCT05892120
• Lead Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital

Brief Summary

This is an experimental study which aims to explore the effectiveness of a smartphone app for medication adherence (MedAdhere app) among schizophrenic patients for eight weeks.

Detailed Description

Schizophrenia is a mental disorder that causes severe functional disabilities and imposes a heavy economic burden. Poor medication adherence is one of the major causes of relapse of psychiatric symptoms in schizophrenic patients. This is an experimental study which aims to explore the effectiveness of a smartphone app for medication adherence (MedAdhere app) among schizophrenic patients for eight weeks.

Study Timeline

• Status Verified: 2023-05
• Study First Submitted: 2023-05-16
• Study Start: 2023-06-01
• Study First Submitted QC: 2023-06-06
• Last Update Submitted: 2023-06-06
• Study First Posted: 2023-06-07
• Last Update Posted: 2023-06-07
• Primary Completion: 2023-07-25
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• schizophrenia
• aged 20 to 65 years
• able to read traditional Chinese
• owning a smartphone
• currently admitted at a psychiatric day-care center

Exclusion Criteria

• Intellectually disabled or severe cognitive function impairment (Dementia)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
experimental group	the MedAdhere app	The experimental group use the MedAdhere app for eight weeks, the PANSS and MMSE were used to assess psychiatric symptoms and cognitive functions before (week 0) and after (week 8) intervention.

Primary Outcome Measures

Name	Time	Method
Medication adherence rate	Change from Baseline Medication adherence' rate at 8 weeks	Utilizing cloud-based platforms to compute the medication adherence rate.
psychiatric symptoms	Change from Baseline psychiatric symptoms at 8 weeks	The positive and negative syndrome scale was used to measure participants' psychiatric symptoms.; Of the 30 items on the scale, seven are positive symptoms, seven are negative symptoms, and 16 are general psychopathology symptoms. Symptom severity for each item is rated according to the anchoring points in the 7-point scale (1 = absent; 7 = extreme) that best describe the symptom (Kay et al., 1987). The PANSS score is the sum of ratings across items, ranging from 7 to 49 for the Positive, Negative Scales, and 16 to 112 and 16 to 112 for the General Psychopathology Scale.
cognitive functions	Change from Baseline cognitive functions at 8 weeks	The Mini-Mental State Examination was used to measure participants' cognitive functions.; The MMSE consists of 15 questions for assessing the following seven cognitive domains: orientation in time and place, memory registration and recall, attention and calculation, and language. The total MMSE score ranged from 0 to 30, and higher scores indicate better cognitive functions.

Trial Locations

Locations (1)

Kaohsiung Medical University; 🇨🇳 Kaohsiung, Taiwan